[Microbiologicaland immunological criteria for estimation of ureaplasmosis treatment efficacy in women].
The role of surface and parietal vaginal microbiocenosis and immunoglobulins in development of infectious process, in prediction of resistance of causative microorganism to antibiotics and treatment efficacy was demonstrated on group of women with ureaplasmosis. Evaluation of anaerobic part of vaginal microbiota contemporary with its aerobic part reliably increased informative value of microbiological test in women with urogenital diseases. There are reasons to include interferon preparations into the complex therapy of ureaplasmosis.
Voropaeva
E A
EA
Afanas'ev
S S
SS
Aleshkin
V A
VA
Vorob'ev
A A
AA
Kudriavtseva
M V
MV
Nesvizhskiĭ
Iu A
IuA
Afanas'ev
M S
MS
Matveevskaia
N S
NS
Panurina
R L
RL
D000282:Administration, Intravaginal; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects / Q000302:isolation & purification; D005260:Female; D005658:Fungi / Q000187:drug effects / Q000302:isolation & purification; D005831:Genital Diseases, Female / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage / Q000032:analysis* / Q000627:therapeutic use*; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D011994:Recombinant Proteins; D013488:Suppositories / Q000627:therapeutic use; D016896:Treatment Outcome; D014509:Ureaplasma / Q000302:isolation & purification; D016869:Ureaplasma Infections / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D014621:Vagina / Q000276:immunology / Q000382:microbiology
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D007136:Immunoglobulins; D007370:Interferon Type I; D011994:Recombinant Proteins; D013488:Suppositories